Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) EPS (Weighted Average and Diluted) (2020 - 2022)

Atea Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 3 years, most recently at -$0.41 for Q4 2022.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.41 for Q4 2022, down 131.06% from a year ago — trailing twelve months through Dec 2022 was -$1.4 (down 204.48% YoY), and the annual figure for FY2025 was -$1.94, up 3.0%.
  • EPS (Weighted Average and Diluted) for Q4 2022 was -$0.41 at Atea Pharmaceuticals, down from -$0.1 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for AVIR hit a ceiling of $2.62 in Q4 2020 and a floor of -$1.74 in Q3 2020.
  • Median EPS (Weighted Average and Diluted) over the past 3 years was -$0.36 (2021), compared with a mean of -$0.05.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 185.0% in 2021 and later tumbled 2000.0% in 2022.
  • Atea Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $2.62 in 2020, then crashed by 49.62% to $1.32 in 2021, then tumbled by 131.06% to -$0.41 in 2022.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.41 (Q4 2022), -$0.1 (Q3 2022), and -$0.38 (Q2 2022) per Business Quant data.